Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on November 6, 2014. The report details a corporate governance event: the expansion of the Board of Directors and the appointment of a new independent director.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to eight members.
- New Appointment: Mr. Bertrand Loy was appointed as an additional Class I independent director.
- Committee Assignment: Mr. Loy was appointed to the Governance Committee.
- Term: Mr. Loy will serve until the 2016 annual meeting of stockholders or until a successor is elected.
Guidance, Outlook, and Compensation Details
The filing outlines specific compensatory arrangements for the new director but provides no financial guidance or outlook for the company's operations.
- Stock Options Grant: On November 13, 2014, Mr. Loy will receive non-qualified stock options.
- Grant Size: The number of shares will be the greater of options with a Black-Scholes cash value of $120,000 or 25,000 shares.
- Terms: The options have a ten-year term with an exercise price equal to the closing stock price on November 13, 2014.
- Vesting Schedule: Options vest in three equal installments on November 13, 2015, 2016, and 2017.
Investor Verification Checklist
- Verify the closing stock price on November 13, 2014, to calculate the exact number of shares granted to Mr. Loy.
- Review the attached press release (Exhibit 99.1) for additional context on Mr. Loy's background.
- Confirm the impact of the new director on the composition of the Governance Committee.
- Note that this filing contains no operational or financial results; refer to the most recent 10-Q or 10-K for financial data.